Episode 214: PREMIUM – two more diabetes treatments that fail us yet again
In episode 214, James and Mike notch the discussion up to a PREMIUM level yet again. We discuss the 2 new gliptin studies, SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) and we find that low and behold these medications lower glucose and have no impact on cardiovascular disease. At the end we lament this lack of cardiovascular benefit by singing a chorus of “Another One Bites The Dust”.
1) SAVOR-TIMI 53 – saxagliptin and cardiovascular outcomes
2) EXAMINE – alogliptin and cardiovascular outcomes